Regulating the dormancy of cancer stem cells: a novel approach to preventing cancer relapse

1. Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168:670–91.

   Google Scholar 

2. Peinado H, Zhang H, Matei IR, Costa-Silva B, Hoshino A, Rodrigues G, et al. Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer. 2017;17:302–17.

   Google Scholar 

3. Yeung KT, Yang J. Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol. 2017;11:28–39.

   Google Scholar 

4. Dillekas H, Rogers MS, Straume O. Are 90% of deaths from cancer caused by metastases? Cancer Med. 2019;8:5574–6.

   Google Scholar 

5. Finlayson J. Celsus: bibliographical demonstration in the library of the faculty of physicians and surgeons of Glasgow, 3rd March, 1892. Glasg Med J. 1892;37:321–48.

   Google Scholar 

6. Basara ML, McCarthy JB, Barnes DW, Furcht LT. Stimulation of haptotaxis and migration of tumor cells by serum spreading factor. Cancer Res. 1985;45:2487–94.

   Google Scholar 

7. Hadfield G. The dormant cancer cell. Br Med J. 1954;2:607–10.

   Google Scholar 

8. Zhang J, Zhang J, Han L, Wu S, Li J, Eaton EN, et al. Inflammation awakens dormant cancer cells by modulating the epithelial-mesenchymal phenotypic state. Proc Natl Acad Sci USA. 2025;122:e2515009122.

   Google Scholar 

9. DeMichele A, Clark AS, Shea E, Bayne LJ, Sterner CJ, Rohn K, et al. Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial. Nat Med. 2025;31:3464–74.

   Google Scholar 

10. Chia SB, Johnson BJ, Hu J, Valenca-Pereira F, Chadeau-Hyam M, Guntoro F, et al. Respiratory viral infections awaken metastatic breast cancer cells in the lungs. Nature. 2025;645:496–506.

    Google Scholar 

11. Ma H, Zhang B, Chen M, Song Z, Zhao Y. Unraveling the mystery of breast cancer dormancy: insights into genetic, receptor, and cellular interactions driving late recurrence. Front Immunol. 2025;16:1657383.

    Google Scholar 

12. Recalde-Percaz L, de la Guia-Lopez I, Linzoain-Agos P, Noguera-Castells A, Rodrigo-Faus M, Jauregui P, et al. Neuropilin-2 upregulation by stromal TGFbeta1 induces lung disseminated tumor cells dormancy escape and promotes metastasis outgrowth. Neoplasia. 2025;68:101220.

    Google Scholar 

13. Friberg S, Nystrom A. Cancer metastases: early dissemination and late recurrences. Cancer Growth Metastasis. 2015;8:43–49.

    Google Scholar 

14. Banys M, Hartkopf AD, Krawczyk N, Kaiser T, Meier-Stiegen F, Fehm T, et al. Dormancy in breast cancer. Breast Cancer (Dove Med Press). 2012;4:183–91.

    Google Scholar 

15. Louis M, Tapia R, Grabill N, Strom P. Dormancy leading to late recurrence in breast cancer: a case of hormone receptor-positive supraclavicular metastasis 10 years after the initial treatment. Cureus. 2024;16:e71586.

    Google Scholar 

16. Gimbrone JrMA, Leapman SB, Cotran RS, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med. 1972;136:261–76.

    Google Scholar 

17. Wang Q, Liang N, Liu C, Li J, Bai Y, Lei S, et al. BEX1 supports the stemness of hepatoblastoma by facilitating Warburg effect in a PPARgamma/PDK1 dependent manner. Br J Cancer. 2023;129:1477–89.

    Google Scholar 

18. Liang N, Yang T, Huang Q, Yu P, Liu C, Chen L, et al. Mechanism of cancer stemness maintenance in human liver cancer. Cell Death Dis. 2022;13:394.

    Google Scholar 

19. Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, Kim HM, et al. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest. 2010;120:3326–39.

    Google Scholar 

20. Wood CR, Wu WT, Yang YS, Yang JS, Xi Y, Yang WJ. From ecology to oncology: To understand cancer stem cell dormancy, ask a Brine shrimp (Artemia). Adv Cancer Res. 2023;158:199–231.

    Google Scholar 

21. Alhasan B, Mikeladze M, Guzhova I, Margulis B. Autophagy, molecular chaperones, and unfolded protein response as promoters of tumor recurrence. Cancer Metastasis Rev. 2023;42:217–54.

    Google Scholar 

22. Barsky SH, McPhail K, Wang J, Dillard J, Beard CJ, Ye Y. True cancer stem cells exhibit relative degrees of dormancy and genomic stability. Neoplasia. 2025;60:101127.

    Google Scholar 

23. Zhao L, Zhang K, He H, Yang Y, Li W, Liu T, et al. The relationship between mesenchymal stem cells and tumor dormancy. Front Cell Dev Biol. 2021;9:731393.

    Google Scholar 

24. Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, La Noce M, et al. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J. 2013;27:13–24.

    Google Scholar 

25. Enderling H. Cancer stem cells and tumor dormancy. Adv Exp Med Biol. 2013;734:55–71.

    Google Scholar 

26. Kusumbe AP, Bapat SA. Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res. 2009;69:9245–53.

    Google Scholar 

27. Carcereri de Prati A, Butturini E, Rigo A, Oppici E, Rossin M, Boriero D, et al. Metastatic breast cancer cells enter a dormant state and express cancer stem cells phenotype under chronic hypoxia. J Cell Biochem. 2017;118:3237–48.

    Google Scholar 

28. La Belle Flynn A, Calhoun BC, Sharma A, Chang JC, Almasan A, Schiemann WP. Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression. Nat Commun. 2019;10:3668.

    Google Scholar 

29. Talukdar S, Bhoopathi P, Emdad L, Das S, Sarkar D, Fisher PB. Dormancy and cancer stem cells: an enigma for cancer therapeutic targeting. Adv Cancer Res. 2019;141:43–84.

30. Wang Q, Bu S, Xin D, Li B, Wang L, Lai D. Autophagy is indispensable for the self-renewal and quiescence of ovarian cancer spheroid cells with stem cell-like properties. Oxid Med Cell Longev. 2018;2018:7010472.

    Google Scholar 

31. Larrue C, Mouche S, Angelino P, Sajot M, Birsen R, Kosmider O, et al. Targeting ferritinophagy impairs quiescent cancer stem cells in acute myeloid leukemia in vitro and in vivo models. Sci Transl Med. 2024;16:eadk1731.

    Google Scholar 

32. Baquero P, Dawson A, Mukhopadhyay A, Kuntz EM, Mitchell R, Olivares O, et al. Targeting quiescent leukemic stem cells using second-generation autophagy inhibitors. Leukemia. 2019;33:981–94.

    Google Scholar 

33. Niharika, Garg M. Understanding the autophagic functions in cancer stem cell maintenance and therapy resistance. Expert Rev Mol Med. 2024;26:e23.

    Google Scholar 

34. Ferdousmakan S, Mansourian D, Seyedi Asl FS, Fathi Z, Maleki-Sheikhabadi F, Afjadi MN, et al. Autophagy induced by metabolic processes leads to solid tumor cell metastatic dormancy and recurrence. Med Oncol. 2025;42:62.

    Google Scholar 

35. Pelaz SG, Ollauri-Ibanez C, Lillo C, Tabernero A. Impairment of autophagic flux participates in the antitumor effects of TAT-Cx43(266-283) in glioblastoma stem cells. Cancers. 2021;13:4262.

    Google Scholar 

36. Ferraresi A, Girone C, Esposito A, Vidoni C, Vallino L, Secomandi E, et al. How autophagy shapes the tumor microenvironment in ovarian cancer. Front Oncol. 2020;10:599915.

    Google Scholar 

37. Yang X, Ye F, Jing Y, Wei L. Autophagy and tumour stem cells. Adv Exp Med Biol. 2020;1207:301–13.

    Google Scholar 

38. Yoshida GJ, Saya H. Molecular pathology underlying the robustness of cancer stem cells. Regen Ther. 2021;17:38–50.

    Google Scholar 

39. Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sanchez N, Marchesini M, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014;514:628–32.

    Google Scholar 

40. Bleau AM, Agliano A, Larzabal L, de Aberasturi AL, Calvo A. Metastatic dormancy: a complex network between cancer stem cells and their microenvironment. Histol Histopathol. 2014;29:1499–510.

    Google Scholar 

41. Sabit H, Abdel-Ghany S, Albrahim Y, Wadan AS, Rashwan S, Arneth R, et al. Bridging the gap in breast cancer dormancy: models, mechanisms, and translational challenges. Pharmaceuticals. 2025;18:961.

    Google Scholar 

42. Nobre AR, Risson E, Singh DK, Di Martino JS, Cheung JF, Wang J, et al. Bone marrow NG2(+)/Nestin(+) mesenchymal stem cells drive DTC dormancy via TGFbeta2. Nat Cancer. 2021;2:327–39.

    Google Scholar 

43. Bushnell GG, Sharma D, Wilmot HC, Zheng M, Fashina TD, Hutchens CM, et al. Natural killer cell regulation of breast cancer stem cells mediates metastatic dormancy. Cancer Res. 2024;84:3337–53.

    Google Scholar 

44. O’ReillyE, Zeinabad HA, Szegezdi E. Hematopoietic versus leukemic stem cell quiescence: challenges and therapeutic opportunities. Blood Rev. 2021;50. 100850.

    Google Scholar 

45. Bort A, Sánchez BG, León C, Nozal L, Mora-Rodríguez JM, Castro F, et al. Metabolic fingerprinting of chemotherapy-resistant prostate cancer stem cells. An untargeted metabolomic approach by liquid chromatography-mass spectrometry. Front Cell Dev Biol. 2022;10:1005675.

    Google Scholar 

46. Chen L, Yang F, Chen S, Tai J. Mechanisms on chemotherapy resistance of colorectal cancer stem cells and research progress of reverse transformation: a mini-review. Front Med. 2022;9:995882.

    Google Scholar 

47. Qiu Y, Qiu S, Deng L, Nie L, Gong L, Liao X, et al. Biomaterial 3D collagen I gel culture model: a novel approach to investigate tumorigenesis and dormancy of bladder cancer cells induced by tumor microenvironment. Biomaterials. 2020;256:120217.

    Google Scholar 

48. Gerstberger S, Jiang Q, Ganesh K. Metastasis. Cell. 2023;186:1564–79.

    Google Scholar 

49. Zhang W, Bado IL, Hu J, Wan YW, Wu L, Wang H, et al. The bone microenvironment invigorates metastatic seeds for further dissemination. Cell. 2021;184:2471–86.e2420.

    Google Scholar 

50. Phan TG, Croucher PI. The dormant cancer cell life cycle. Nat Rev Cancer. 2020;20:398–411.

    Google Scholar 

51. Boyle CE, Hou T. Late recurrence/metastasis of acinic cell carcinoma after 10 years of resection: a case series and literature review. Ear Nose Throat J. 2025;4:1455613251347174.

52. Abebe K, Orholt M, Bak EEF, Larsen A, Wagenblast AL, Schmidt G, et al. Prognosis and follow-up recommendations for subcutaneous and dermal leiomyosarcoma: local recurrence, metastasis, and overall survival in a Danish nationwide cohort of 661 patients. J Surg Oncol. 2025;132:1076–85.

    Google Scholar 

53. Zhang Y, Liang Y, Liu Z, Zhang H, Gao Z, Wang J. Efficacy of radioactive 125I seed implantation in treating inoperable or refused operation head and neck cancers. J Cancer Res Ther. 2024;20:642–50.

    Google Scholar 

54. Fujimoto H, Yoshihara M, Ricciardelli C, Tano S, Iyoshi S, Miyamoto E, et al. Aging affects regrowth of stealthperitoneal dissemination of advanced ovarian cancer: a multicenter retrospective cohort study. Sci Rep. 2024;14:23537.

    Google Scholar 

55. Farzaliyeva A, Ramazanoglu MN, Safak A, Oguz A, Akcali Z, Altundag O, et al. Recurrence of hepatocellular carcinoma after liver transplant: a single-center experience. Exp Clin Transpl. 2025;23:542–5.

    Google Scholar 

56. Erdogan AM, Bozkurt FK. Epithelial-myoepithelial carcinoma of the parotid gland: Case report. Int J Surg Case Rep. 2025;135:111914.

    Google Scholar 

57. Rusu P, Shao C, Neuerburg A, Acikgoz AA, Wu Y, Zou P, et al. GPD1 specifically marks dormant glioma stem cells with a distinct metabolic profile. Cell Stem Cell. 2019;25:241–57.e248.

    Google Scholar 

58. Tamai K, Nakamura-Shima M, Shibuya-Takahashi R, Kanno SI, Yasui A, Mochizuki M, et al. BEX2 suppresses mitochondrial activity and is required for dormant cancer stem cell maintenance in intrahepatic cholangiocarcinoma. Sci Rep. 2020;10:21592.

    Google Scholar 

59. Fukushi D, Shibuya-Takahashi R, Mochizuki M, Fujimori H, Kogure T, Sugai T, et al. BEX2 is required for maintaining dormant cancer stem cells in hepatocellular carcinoma. Cancer Sci. 2021;112:4580–92.

    Google Scholar 

60. Dwyer S, Ruth J, Seidel HE, Raz AA, Chodosh LA. Autophagy is required for mammary tumor recurrence by promoting dormant tumor cell survival following therapy. Breast Cancer Res. 2024;26:143.

    Google Scholar 

61. Nishikawa S, Dewi DL, Ishii H, Konno M, Haraguchi N, Kano Y, et al. Transcriptomic study of dormant gastrointestinal cancer stem cells. Int J Oncol. 2012;41:979–84.

    Google Scholar 

62. Wei JR, Zhang B, Zhang Y, Chen WM, Zhang XP, Zeng TT, et al. QSOX1 facilitates dormant esophageal cancer stem cells to evade immune elimination via PD-L1 upregulation and CD8 T cell exclusion. Proc Natl Acad Sci USA. 2024;121:e2407506121.

    Google Scholar 

63. Dong C, Liu Y, Chong S, Zeng J, Bian Z, Chen X, et al. Deciphering dormant cells of lung adenocarcinoma: prognostic insights from o-glycosylation-related tumor dormancy genes using machine learning. Int J Mol Sci. 2024;25:9502.

    Google Scholar 

64. Sui Y, Hu W, Zhang W, Li D, Zhu H, You Q, et al. Insights into homeobox B9: a propeller for metastasis in dormant prostate cancer progenitor cells. Br J Cancer. 2021;125:1003–15.

    Google Scholar 

65. Deng M, Huang PZ, Huang ZY, Chen TT, Luo X, Liao CY, et al. SOX2 control activation of dormant prostate cancer cells in bone metastases by promoting CCNE2 gene expression. Am J Clin Exp Urol. 2024;12:375–88.

    Google Scholar 

66. Di Martino JS, Nobre AR, Mondal C, Taha I, Farias EF, Fertig EJ, et al. A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy. Nat Cancer. 2022;3:90–107.

    Google Scholar 

67. Pathak L, Pal B, Talukdar J, Saikia PJ, Sandhya S, Tasabehji W, et al. Hypoxia-driven mobilization of altruistic cancer stem cells in platinum-treated head and neck cancer. Front Immunol. 2024;15:1336882.

    Google Scholar 

68. Jia Q, Yang F, Huang W, Zhang Y, Bao B, Li K, et al. Low levels of Sox2 are required for melanoma tumor-repopulating cell dormancy. Theranostics. 2019;9:424–35.

    Google Scholar 

69. Liu Y, Lv J, Liu J, Liang X, Jin X, Xie J, et al. STAT3/p53 pathway activation disrupts IFN-beta-induced dormancy in tumor-repopulating cells. J Clin Invest. 2018;128:1057–73.

    Google Scholar 

70. Bhartiya D, Patel H, Ganguly R, Shaikh A, Shukla Y, Sharma D, et al. Novel insights into adult and cancer stem cell biology. Stem Cells Dev. 2018;27:1527–39.

    Google Scholar 

71. Liu Y, Lv J, Liang X, Yin X, Zhang L, Chen D, et al. Fibrin stiffness mediates dormancy of tumor-repopulating cells via a Cdc42-driven Tet2 epigenetic program. Cancer Res. 2018;78:3926–37.

    Google Scholar 

72. Ohta Y, Fujii M, Takahashi S, Takano A, Nanki K, Matano M, et al. Cell-matrix interface regulates dormancy in human colon cancer stem cells. Nature. 2022;608:784–94.

    Google Scholar 

73. Siddharth S, Das S, Nayak A, Kundu CN. SURVIVIN as a marker for quiescent-breast cancer stem cells: an intermediate, adherent, pre-requisite phase of breast cancer metastasis. Clin Exp Metastasis. 2016;33:661–75.

    Google Scholar 

74. Wu R, RoyAM, Tokumaru Y, Gandhi S, Asaoka M, Oshi M, et al. NR2F1, a tumor dormancy marker, is expressed predominantly in cancer-associated fibroblasts and is associated with suppressed breast cancer cell proliferation. Cancers. 2022;14:2962.

    Google Scholar 

75. Khalil BD, Sanchez R, Rahman T, Rodriguez-Tirado C, Moritsch S, Martinez AR, et al. An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy. J Exp Med. 2022;219:e20210836.

    Google Scholar 

76. Liu Y, Zhang P, Wu Q, Fang H, Wang Y, Xiao Y, et al. Long non-coding RNA NR2F1-AS1 induces breast cancer lung metastatic dormancy by regulating NR2F1 and DeltaNp63. Nat Commun. 2021;12:5232.

    Google Scholar 

77. Borgen E, Rypdal MC, Sosa MS, Renolen A, Schlichting E, Lonning PE, et al. NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients. Breast Cancer Res. 2018;20:120.

    Google Scholar 

78. Sosa MS, Parikh F, Maia AG, Estrada Y, Bosch A, Bragado P, et al. NR2F1 controls tumour cell dormancy via SOX9- and RARbeta-driven quiescence programmes. Nat Commun. 2015;6:6170.

    Google Scholar 

79. Rodriguez-Tirado C, Kale N, Carlini MJ, Shrivastava N, Rodrigues AA, Khalil BD, et al. NR2F1 is a barrier to dissemination of early-stage breast cancer cells. Cancer Res. 2022;82:2313–26.

    Google Scholar 

80. Tiago M, Purwin TJ, Stefanski CD, da Silva RO, Fane ME, Chhabra Y, et al. Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma. J Clin Investig. 2025;135:e178446.

    Google Scholar 

81. Jahanshir E, Llamas J, Kim Y, Biju K, Oak S, Gnedeva K. The Hippo pathway and p27(Kip1) cooperate to suppress mitotic regeneration in the organ of Corti and the retina. Proc Natl Acad Sci USA. 2025;122:e2411313122.

    Google Scholar 

82. Lu R, Wang Q, Li J, Miao D. P27 deletion enhances hematopoiesis by paracrine action of IL22 secreted from bone marrow mesenchymal stem cells. Am J Transl Res. 2020;12:787–99.

    Google Scholar 

83. Jeong Y, Deveza L, Ortinau L, Lei K, Dawson JR, Park D. Identification of LRP1+CD13+ human periosteal stem cells that require LRP1 for bone repair. JCI Insight. 2024;9:e173831.

    Google Scholar 

84. Sadoune M, Mourad J, Luc C, Ragot H, Mateo P, Polidano E, et al. Qsox1 contributes to vascular remodelling in response to hypertension. J Vasc Res. 2025;62:289–303.

    Google Scholar 

85. Ilani T, Reznik N, Yeshaya N, Feldman T, Vilela P, Lansky Z, et al. The disulfide catalyst QSOX1 maintains the colon mucosal barrier by regulating Golgi glycosyltransferases. EMBO J. 2023;42:e111869.

    Google Scholar 

86. Mu N, Wang Y, Li X, Du Z, Wu Y, Su M, et al. Crotonylated BEX2 interacts with NDP52 and enhances mitophagy to modulate chemotherapeutic agent-induced apoptosis in non-small-cell lung cancer cells. Cell Death Dis. 2023;14:645.

    Google Scholar 

87. Tan Y, Hu Y, Xiao Q, Tang Y, Chen H, He J, et al. Silencing of brain-expressed X-linked 2 (BEX2) promotes colorectal cancer metastasis through the hedgehog signaling pathway. Int J Biol Sci. 2020;16:228–38.

    Google Scholar 

88. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 1994;78:67–74.

    Google Scholar 

89. Poon RY, Toyoshima H, Hunter T. Redistribution of the CDK inhibitor p27 between different cyclins. CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation. Mol Biol Cell. 1995;6:1197–213.

    Google Scholar 

90. Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, et al. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science. 1995;267:1018–21.

    Google Scholar 

91. Martin-Padura I, Marighetti P, Agliano A, Colombo F, Larzabal L, Redrado M, et al. Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. Lab Invest. 2012;92:952–66.

    Google Scholar 

92. Look AT, Ashmun RA, Shapiro LH, Peiper SC. Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J Clin Invest. 1989;83:1299–307.

    Google Scholar 

93. Luo L, Zhang H, Zhang S, Luo C, Kan X, Lv J, et al. Extracellular vesicle-derived silk fibroin nanoparticles loaded with MFGE8 accelerate skin ulcer healing by targeting the vascular endothelial cells. J Nanobiotechnology. 2023;21:455.

    Google Scholar 

94. Trencsenyi G, Enyedi KN, Mezo G, Halmos G, Kepes Z. NGR-based radiopharmaceuticals for angiogenesis imaging: a preclinical review. Int J Mol Sci. 2023;24:12675.

    Google Scholar 

95. Diaz-Alvarez L, Martinez-Sanchez ME, Gray E, Perez-Figueroa E, Ortega E. Aminopeptidase N/CD13 crosslinking promotes the activation and membrane expression of integrin CD11b/CD18. Biomolecules. 2023;13:1488.

    Google Scholar 

96. Park SC, Lim HS, Lee JR. Structural switching of Arabidopsis QSOX1 defines stress-dependent chaperone and defense functions. Biochem Biophys Res Commun. 2025;783:152637.

    Google Scholar 

97. Feldman T, Grossman-Haham I, Elkis Y, Vilela P, Moskovits N, Barshack I, et al. Inhibition of fibroblast-secreted QSOX1 perturbs the extracellular matrix in the tumor microenvironment and decreases tumor growth and metastasis in murine cancer models. Oncotarget. 2020;11:386–98.

    Google Scholar 

98. Knutsvik G, Collett K, Arnes J, Akslen LA, Stefansson IM. QSOX1 expression is associated with aggressive tumor features and reduced survival in breast carcinomas. Mod Pathol. 2016;29:1485–91.

    Google Scholar 

99. Lake DF, Faigel DO. The emerging role of QSOX1 in cancer. Antioxid Redox Signal. 2014;21:485–96.

    Google Scholar 

100. Das P, Siegers GM, Postovit LM. Illuminating luminal B: QSOX1 as a subtype-specific biomarker. Breast Cancer Res. 2013;15:104.

     Google Scholar 

101. Katchman BA, Ocal IT, Cunliffe HE, Chang YH, Hostetter G, Watanabe A, et al. Expression of quiescin sulfhydryl oxidase 1 is associated with a highly invasive phenotype and correlates with a poor prognosis in Luminal B breast cancer. Breast Cancer Res. 2013;15:R28.

     Google Scholar 

102. Uchida Y, Tanaka S, Aihara A, Adikrisna R, Yoshitake K, Matsumura S, et al. Analogy between sphere-forming ability and stemness of human hepatoma cells. Oncol Rep. 2010;24:1147–51.

     Google Scholar 

103. Dittmer J. Mechanisms governing metastatic dormancy in breast cancer. Semin Cancer Biol. 2017;44:72–82.

     Google Scholar 

104. Tallon de Lara P, Castanon H, Vermeer M, Nunez N, Silina K, Sobottka B, et al. CD39(+)PD-1(+)CD8(+) T cells mediate metastatic dormancy in breast cancer. Nat Commun. 2021;12:769.

     Google Scholar 

105. Romero I, Garrido F, García-Lora AM. Metastases in immune-mediated dormancy: a new opportunity for targeting cancer. Cancer Res. 2014;74:6750–7.

     Google Scholar 

106. Correia AL, Guimarães JC, Auf der Maur P, De Silva D, Trefny MP, Okamoto R, et al. Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy. Nature. 2021;594:566–71.

     Google Scholar 

107. Michelatti D, Beyes S, Bernardis C, Negri ML, Morelli L, Bediaga NG, et al. Oncogenic enhancers prime quiescent metastatic cells to escape NK immune surveillance by eliciting transcriptional memory. Nat Commun. 2024;15:2198.

     Google Scholar 

108. Nair VR, Malladi S. Mouse models to study natural killer cell-mediated immunosurveillance and metastatic latency. Methods Mol Biol. 2019;1884:141–50.

     Google Scholar 

109. Moretta A. Molecular mechanisms in cell-mediated cytotoxicity. Cell. 1997;90:13–18.

     Google Scholar 

110. Orr MT, Lanier LL. Natural killer cell education and tolerance. Cell. 2010;142:847–56.

     Google Scholar 

111. Takagi S, Minakuchi J, Okawa H, Yata J. Interferon-induced resistance of tumor target cells against lysis by interleukin-2-activated killer cells. Tohoku J Exp Med. 1989;157:131–6.

     Google Scholar 

112. Zhang H, Ding Y, Gu L, Guo A, Duan W, Wang X, et al. Macrophage regulation of tumor cell dormancy and the dormant niche: an overview in solid tumors. Cancer Metastasis Rev. 2025;44:63.

     Google Scholar 

113. Borriello L, Coste A, Traub B, Sharma VP, Karagiannis GS, Lin Y, et al. Primary tumor-associated macrophages activate programs of invasion and dormancy in disseminating tumor cells. Nat Commun. 2022;13:626.

     Google Scholar 

114. Lund WA. Winter is coming: Tumor cells go into hibernation. Sci Transl Med. 2017;15. eaam6063.

     Google Scholar 

115. Todd VM, Vecchi LA 3rd, Clements ME, Snow KP, Ontko CD, Himmel L, et al. Hypoxia-inducible factor signaling in breast tumors controls spontaneous tumor dissemination in a site-specific manner. Commun Biol. 2021;4:1122.

     Google Scholar 

116. Cho J. Understanding tumor dormancy: from experimental models to mechanisms and therapeutic strategies. Biomol Ther. 2025;33:770–84.

     Google Scholar 

117. Fluegen G, Avivar-Valderas A, Wang Y, Padgen MR, Williams JK, Nobre AR, et al. Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments. Nat Cell Biol. 2017;19:120–32.

     Google Scholar 

118. Pan Y, Yuan C, Zeng C, Sun C, Xia L, Wang G, et al. Cancer stem cells and niches: challenges in immunotherapy resistance. Mol Cancer. 2025;24:52.

     Google Scholar 

119. Ji S, Yu H, Zhou D, Fan X, Duan Y, Tan Y, et al. Cancer stem cell-derived CHI3L1 activates the MAF/CTLA4 signaling pathway to promote immune escape in triple-negative breast cancer. J Transl Med. 2023;21:721.

     Google Scholar 

120. Trotter TN, Dagotto CE, Serra D, Wang T, Yang X, Acharya CR, et al. Dormant tumors circumvent tumor-specific adaptive immunity by establishing a Treg-dominated niche via DKK3. JCI Insight. 2023;8:e174458.

     Google Scholar 

121. Ono M, Kosaka N, Tominaga N, Yoshioka Y, Takeshita F, Takahashi RU, et al. Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Sci Signal. 2014;7:ra63.

     Google Scholar 

122. Bliss SA, Sinha G, Sandiford OA, Williams LM, Engelberth DJ, Guiro K, et al. Mesenchymal stem cell-derived exosomes stimulate cycling quiescence and early breast cancer dormancy in bone marrow. Cancer Res. 2016;76:5832–44.

     Google Scholar 

123. Shiozawa Y, Berry JE, Eber MR, Jung Y, Yumoto K, Cackowski FC, et al. The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer. Oncotarget. 2016;7:41217–32.

     Google Scholar 

124. Alhasan BA, Gordeev SA, Knyazeva AR, Aleksandrova KV, Margulis BA, Guzhova IV, et al. The mTOR pathway in pluripotent stem cells: lessons for understanding cancer cell dormancy. Membranes. 2021;11:858.

     Google Scholar 

125. Cho J, Min HY, Lee HJ, Hyun SY, Sim JY, Noh M, et al. RGS2-mediated translational control mediates cancer cell dormancy and tumor relapse. J Clin Investig. 2021;131:e136779.

     Google Scholar 

126. Lechman ER, Gentner B, Ng SW, Schoof EM, van Galen P, Kennedy JA, et al. miR-126 regulates distinct self-renewal outcomes in normal and malignant hematopoietic stem cells. Cancer Cell. 2016;29:214–28.

     Google Scholar 

127. Fang Y, Yang Y, Hua C, Xu S, Zhou M, Guo H, et al. Rictor has a pivotal role in maintaining quiescence as well as stemness of leukemia stem cells in MLL-driven leukemia. Leukemia. 2017;31:414–22.

     Google Scholar 

128. Martins-Neves SR, Sampaio-Ribeiro G, Gomes CMF. Self-renewal and pluripotency in osteosarcoma stem cells’ chemoresistance: notch, hedgehog, and Wnt/beta-catenin interplay with embryonic markers. Int J Mol Sci. 2023;24:8401.

     Google Scholar 

129. Shang T, Jia Z, Li J, Cao H, Xu H, Cong L, et al. Unraveling the triad of hypoxia, cancer cell stemness, and drug resistance. J Hematol Oncol. 2025;18:32.

     Google Scholar 

130. Zhou L, Wang D, Sheng D, Xu J, Chen W, Qin Y, et al. NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer. Theranostics. 2020;10:2405–21.

     Google Scholar 

131. Ye S, Ding YF, Jia WH, Liu XL, Feng JY, Zhu Q, et al. SET domain-containing protein 4 epigenetically controls breast cancer stem cell quiescence. Cancer Res. 2019;79:4729–43.

     Google Scholar 

132. Desai K, Wanggou S, Luis E, Whetstone H, Yu C, Vanner RJ, et al. OLIG2 mediates a rare targetable stem cell fate transition in sonic hedgehog medulloblastoma. Nat Commun. 2025;16:1092.

     Google Scholar 

133. Lainez-González D, Alonso-Aguado AB, Alonso-Domínguez JM. Understanding the Wnt signaling pathway in acute myeloid leukemia stem cells: a feasible key against relapses. Biology. 2023;12:683.

     Google Scholar 

134. Sheng Y, Yu C, Liu Y, Hu C, Ma R, Lu X, et al. FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML. Nat Commun. 2020;11:928.

     Google Scholar 

135. Robertson FL, O’Duibhir E, Gangoso E, Bressan RB, Bulstrode H, Marques-Torrejon MA, et al. Elevated FOXG1 in glioblastoma stem cells cooperates with Wnt/beta-catenin to induce exit from quiescence. Cell Rep. 2023;42:112561.

     Google Scholar 

136. Touil Y, Igoudjil W, Corvaisier M, Dessein AF, Vandomme J, Monte D, et al. Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis. Clin Cancer Res. 2014;20:837–46.

     Google Scholar 

137. Wang Q, Liang N, Yang T, Li Y, Li J, Huang Q, et al. DNMT1-mediated methylation of BEX1 regulates stemness and tumorigenicity in liver cancer. J Hepatol. 2021;75:1142–53.

     Google Scholar 

138. Kleffel S, Schatton T. Tumor dormancy and cancer stem cells: two sides of the same coin? Adv Exp Med Biol. 2013;734:145–79.

     Google Scholar 

139. Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood. 2002;99:507–12.

     Google Scholar 

140. Morgan J, Jackson JD, Zheng X, Pandey SK, Pandey RK. Substrate affinity of photosensitizers derived from chlorophyll a: the ABCG2 transporter affects the phototoxic response of side population stem cell-like cancer cells to photodynamic therapy. Mol Pharm. 2010;7:1789–804.

     Google Scholar 

141. Niechi I, Erices JI, Carrillo-Beltrán D, Uribe-Ojeda A, Torres A, Rocha JD, et al. Cancer stem cell and aggressiveness traits are promoted by stable endothelin-converting enzyme-1c in glioblastoma cells. Cells. 2023;12:506.

     Google Scholar 

142. Ghorbian S. Cancer cell plasticity and therapeutic resistance: mechanisms, crosstalk, and translational perspectives. Hereditas. 2025;162:188.

     Google Scholar 

143. Kongtanawanich K, Prasopporn S, Jamnongsong S, Thongsin N, Payungwong T, Okada S, et al. A live single-cell reporter system reveals drug-induced plasticity of a cancer stem cell-like population in cholangiocarcinoma. Sci Rep. 2024;14:22619.

     Google Scholar 

144. Hembram KC, Dash SR, Das B, Sethy C, Chatterjee S, Bindhani BK, et al. Quinacrine-based gold hybrid nanoparticles caused apoptosis through modulating the replication fork in oral cancer stem cells. Mol Pharm. 2020;17:2463–72.

     Google Scholar 

145. Gies S, Melchior P, Molnar I, Olmes G, Stroeder R, Tanzer T, et al. PD-L1(+) CD49f(+) CD133(+) circulating tumor cells predict outcome of patients with vulvar or cervical cancer after radio- and chemoradiotherapy. J Transl Med. 2025;23:321.

     Google Scholar 

146. Sriratanasak N, Chunhacha P, Ei ZZ, Chanvorachote P. Cisplatin Induces Senescent lung cancer cell-mediated stemness induction via grp78/akt-dependent mechanism. Biomedicines. 2022;10:2703.

     Google Scholar 

147. Gimeno-Valiente F, Castignani C, Larose Cadieux E, Mensah NE, Liu X, Chen K, et al. DNA methylation cooperates with genomic alterations during non-small cell lung cancer evolution. Nat Genet. 2025;57:2226–37.

     Google Scholar 

148. Ferrer AI, Trinidad JR, Sandiford O, Etchegaray JP, Rameshwar P. Epigenetic dynamics in cancer stem cell dormancy. Cancer Metastasis Rev. 2020;39:721–38.

     Google Scholar 

149. Chen X, Li X, Zhao B, Shang D, Zhong M, Deng C, et al. Dormancy activation mechanism of oral cavity cancer stem cells. Tumour Biol. 2015;36:5551–9.

     Google Scholar 

150. Lee EJ, Rath P, Liu J, Ryu D, Pei L, Noonepalle SK, et al. Identification of global DNA methylation signatures in glioblastoma-derived cancer stem cells. J Genet Genomics. 2015;42:355–71.

     Google Scholar 

151. Nguyen NTB, Gevers S, Kok RNU, Burgering LM, Neikes H, Akkerman N, et al. Lactate controls cancer stemness and plasticity through epigenetic regulation. Cell Metab. 2025;37:903–19.e910.

     Google Scholar 

152. Mihalas AB, Arora S, O’Connor SA, Feldman HM, Cucinotta CE, Mitchell K, et al. KAT5 regulates neurodevelopmental states associated with G0-like populations in glioblastoma. Nat Commun. 2025;16:4327.

     Google Scholar 

153. Wada T, Koyama D, Kikuchi J, Honda H, Furukawa Y. Overexpression of the shortest isoform of histone demethylase LSD1 primes hematopoietic stem cells for malignant transformation. Blood. 2015;125:3731–46.

     Google Scholar 

154. Ferrer-Díaz AI, Sinha G, Petryna A, González-Bermejo R, Kenfack Y, Adetayo O, et al. Revealing role of epigenetic modifiers and DNA oxidation in cell-autonomous regulation of Cancer stem cells. Cell Commun Signal. 2024;22:119.

     Google Scholar 

155. Fujita S, Honma D, Adachi N, Araki K, Takamatsu E, Katsumoto T, et al. Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia. Leukemia. 2018;32:855–64.

     Google Scholar 

156. Pommier A, Anaparthy N, Memos N, Kelley ZL, Gouronnec A, Yan R, et al. Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science. 2018;360:eaao4908.

     Google Scholar 

157. Landum F, Correia AL. A Live Tracker of dormant disseminated tumor cells. Methods Mol Biol. 2024;2811:155–64.

     Google Scholar 

158. Pulianmackal AJ, Sun D, Yumoto K, Li Z, Chen YC, Patel MV, et al. Monitoring spontaneous quiescence and asynchronous proliferation-quiescence decisions in prostate cancer cells. Front Cell Dev Biol. 2021;9:728663.

     Google Scholar 

159. Bi L, Xie C, Yao M, Thae Hnit SS, Vignarajan S, Wang Y, et al. The histone chaperone complex FACT promotes proliferative switch of G(0) cancer cells. Int J Cancer. 2019;145:164–78.

     Google Scholar 

160. Oki T, Nishimura K, Kitaura J, Togami K, Maehara A, Izawa K, et al. A novel cell-cycle-indicator, mVenus-p27K-, identifies quiescent cells and visualizes G0-G1 transition. Sci Rep. 2014;4:4012.

     Google Scholar 

161. Rubsam LZ, Boucher PD, Murphy PJ, KuKuruga M, Shewach DS. Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells. Cancer Res. 1999;59:669–75.

     Google Scholar 

162. Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell. 2010;7:299–313.

     Google Scholar 

163. Paczuska J, Switalska M, Nowak M, Kielbowicz Z. Effectiveness of CO(2) laser in an experimental mammary gland adenocarcinoma model. Vet Comp Oncol. 2018;16:47–54.

     Google Scholar 

164. Connor AA, Denroche RE, Jang GH, Timms L, Kalimuthu SN, Selander I, et al. Association of distinct mutational signatures with correlates of increased immune activity in pancreatic ductal adenocarcinoma. JAMA Oncol. 2017;3:774–83.

     Google Scholar 

165. Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA. 2013;110:20212–7.

     Google Scholar 

166. Poschke I, Faryna M, Bergmann F, Flossdorf M, Lauenstein C, Hermes J, et al. Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. Oncoimmunology. 2016;5:e1240859.

     Google Scholar 

167. Falkenberg C, Sorensen DB, Hansen CH, Toft MF, Hansen AK. Pre-immunization of diet-induced obese male mice with inactivated pathogens increases power in a liraglutide intervention study. Lab Anim. 2025;59:203–14.

     Google Scholar 

168. He D, Wu Q, Tian P, Liu Y, Jia Z, Li Z, et al. Chemotherapy awakens dormant cancer cells in lung by inducing neutrophil extracellular traps. Cancer Cell. 2025;43:1622–1636.e1627.

     Google Scholar 

169. Bakhshandeh S, Heras U, Taieb HM, Varadarajan AR, Lissek SM, Hucker SM, et al. Dormancy-inducing 3D engineered matrix uncovers mechanosensitive and drug-protective FHL2-p21 signaling axis. Sci Adv. 2024;10:eadr3997.

     Google Scholar 

170. Liu Z, Vunjak-Novakovic G. Modeling tumor microenvironments using custom-designed biomaterial scaffolds. Curr Opin Chem Eng. 2016;11:94–105.

     Google Scholar 

171. Begum J, Day W, Henderson C, Purewal S, Cerveira J, Summers H, et al. A method for evaluating the use of fluorescent dyes to track proliferation in cell lines by dye dilution. Cytom A. 2013;83:1085–95.

     Google Scholar 

172. Cho J, Min HY, Lee HY. Isolation of slow-cycling cancer cells from lung patient-derived xenograft using carboxyfluorescein-succinimidyl ester retention-mediated cell sorting. STAR Protoc. 2023;4:102167.

     Google Scholar 

173. Lee HR, Leslie F, Azarin SM. A facile in vitro platform to study cancer cell dormancy under hypoxic microenvironments using CoCl(2). J Biol Eng. 2018;12:12.

     Google Scholar 

174. Barkan D, Kleinman H, Simmons JL, Asmussen H, Kamaraju AK, Hoenorhoff MJ, et al. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res. 2008;68:6241–50.

     Google Scholar 

175. Katsura Y, Ohara T, Noma K, Ninomiya T, Kashima H, Kato T, et al. A novel combination cancer therapy with iron chelator targeting cancer stem cells via suppressing stemness. Cancers. 2019;11:177.

     Google Scholar 

176. Wenzel C, Riefke B, Grundemann S, Krebs A, Christian S, Prinz F, et al. 3D high-content screening for the identification of compounds that target cells in dormant tumor spheroid regions. Exp Cell Res. 2014;323:131–43.

     Google Scholar 

177. Essers MA, Trumpp A. Targeting leukemic stem cells by breaking their dormancy. Mol Oncol. 2010;4:443–50.

     Google Scholar 

178. Fu C, Zhou N, Zhao Y, Duan J, Xu H, Wang Y. Dendritic cells loaded with CD44(+) CT-26 colon cell lysate evoke potent antitumor immune responses. Oncol Lett. 2019;18:5897–904.

     Google Scholar 

179. Baek BS, Park H, Choi JW, Lee EY, Seong SY. HIFU-CCL19/21 axis enhances dendritic cell vaccine efficacy in the tumor microenvironment. Pharmaceutics. 2025;17:65.

     Google Scholar 

180. Erkisa M, Aztopal N, Erturk E, Ulukaya E, Yilmaz VT, Ari F. Combination of Histone deacetylase inhibitor with Cu(II) 5,5-diethylbarbiturate complex induces apoptosis in breast cancer stem cells: a promising novel approach. Anticancer Agents Med Chem. 2021;21:1850–60.

     Google Scholar 

181. Wongtrakoongate P. Epigenetic therapy of cancer stem and progenitor cells by targeting DNA methylation machineries. World J Stem Cells. 2015;7:137–48.

     Google Scholar 

182. Bae W, Ra EA, Lee MH. Epigenetic regulation of reprogramming and pluripotency: insights from histone modifications and their implications for cancer stem cell therapies. Front Cell Dev Biol. 2025;13:1559183.

     Google Scholar 

183. El Touny LH, Vieira A, Mendoza A, Khanna C, Hoenerhoff MJ, Green JE. Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells. J Clin Investig. 2014;124:156–68.

     Google Scholar 

184. Mehdizadeh R, Shariatpanahi SP, Goliaei B, Ruegg C. Targeting myeloid-derived suppressor cells in combination with tumor cell vaccination predicts anti-tumor immunity and breast cancer dormancy: an in silico experiment. Sci Rep. 2023;13:5875.

     Google Scholar 

185. Yuan S, Wang F, Chen G, Zhang H, Feng L, Wang L, et al. Effective elimination of cancer stem cells by a novel drug combination strategy. Stem Cells. 2013;31:23–34.

     Google Scholar 

186. Hong G, Chang JE. Enhancing cancer treatment through combined approaches: photodynamic therapy in concert with other modalities. Pharmaceutics. 2024;16:1420.

     Google Scholar 

187. Casson J, Davies OG, Smith CA, Dalby MJ, Berry CC. Mesenchymal stem cell-derived extracellular vesicles may promote breast cancer cell dormancy. J Tissue Eng. 2018;9:2041731418810093.

     Google Scholar 

188. Damen MPF, van Rheenen J, Scheele C. Targeting dormant tumor cells to prevent cancer recurrence. FEBS J. 2021;288:6286–303.

     Google Scholar 

189. Jahanban-Esfahlan R, Seidi K, Manjili MH, Jahanban-Esfahlan A, Javaheri T, Zare P. Tumor cell dormancy: threat or opportunity in the fight against cancer. Cancers. 2019;11:1207.

     Google Scholar 

190. Tamamouna V, Pavlou E, Neophytou CM, Papageorgis P, Costeas P. Regulation of metastatic tumor dormancy and emerging opportunities for therapeutic intervention. Int J Mol Sci. 2022;23:13931.

     Google Scholar 

191. Tsuyuzaki H, Ujiie R, Sato M. Wake-up alarm: virtual time-lapse gene expression landscape illuminates mechanisms underlying dormancy breaking of germinating spores. Curr Genet. 2021;67:519–34.

     Google Scholar 

192. Melzer C, Ohe JV, Luo T, Hass R. Spontaneous fusion of MSC with breast cancer cells can generate tumor dormancy. Int J Mol Sci. 2021;22:5930.

     Google Scholar 

193. Gaedicke S, Braun F, Prasad S, Machein M, Firat E, Hettich M, et al. Noninvasive positron emission tomography and fluorescence imaging of CD133+ tumor stem cells. Proc Natl Acad Sci USA. 2014;111:E692–701.

     Google Scholar 

194. Goddard ET, Fischer J, Schedin P. A portal vein injection model to study liver metastasis of breast cancer. J Vis Exp. 2016;118:54903.

     Google Scholar 

195. Tivari S, Korah R, Lindy M, Wieder R. An in vitro dormancy model of estrogen-sensitive breast cancer in the bone marrow: a tool for molecular mechanism studies and hypothesis generation. J Vis Exp. 2015;100:e52672.

     Google Scholar 

196. Zhang M, Peng R, Wang H, Yang Z, Zhang H, Zhang Y, et al. Nanog mediated by FAO/ACLY signaling induces cellular dormancy in colorectal cancer cells. Cell Death Dis. 2022;13:159.

     Google Scholar 

197. Prahlad V, Gelman IH. From worms to tumors: conserved strategies of cellular arrest and survival governing dormancy. Cancer Res. 2025;85:4585–99.

     Google Scholar 

198. Valverde A, Naqvi AR. A protocol for modeling human bone inflammation: co-culture of osteoblasts and osteoclasts exposed to different inflammatory microenvironments. Methods Protoc. 2025;8:97.

     Google Scholar 

Download references